How do you approach breast hypofractionation RNI with the results of the Skagen Trial 1?  

Do the results from the Skagen Trial 1 at ESTRO 2025 showing worse all-cause mortality and breast cancer-specific mortality in the hypofrac arm, warrant caution with using this approach, especially in light of the positive data from RT Charm?